About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Stakes High for Pharmaceutical Industry Sectors
Despite the contentious nature of the health reform debate in Congress, there is significant support from many groups—such as business and labor—for changing the practice of health care delivery, reducing costs, improving effectiveness, and covering the uninsured.
A Comparison with Other Oral Antidiabetic Agents
In a study of a largely minority population of diabetic Medicaid recipients, rosi-
glitazone (Avandia) was linked to an increase in myocardial infarction and stroke, whereas pioglitazone (Actos) and thiazolidinediones as a class did not show such an association.
Fadia T. Shaya, PhD, MPH; Zhiqiang Lu, BSPharm, PhD Candidate; Kyongsei Sohn, PhD, MBA; and Matthew R. Weir, MD
Therapies for Insomnia and Comorbid Chronic Obstructive Pulmonary Disease with a Focus on Ramelteon (Rozerem)
The authors discuss the relationship between sleep-related disorders and pulmonary disease and summarize the risks and benefits of medications for insomnia: the older benzodiazepine receptor agonists (e.g., flurazepam, temazepam, triazolam); the newer non-benzodiazepine agents (e.g., zolpidem, zaleplon, eszopiclone); and ramelteon, a promising melatonin receptor agonist.
Jack Greenberg, MD, and J. B. Goss, RPh, PhD
Topics covered include prasugrel (Effient) for reducing cardiovascular events in patients with acute coronary syndrome; ferumoxytol injection (Feraheme) for iron-deficiency anemia in adults with chronic kidney disease; and dronedarone (Multaq) for the treatment of atrial fibrillation.
Marvin M. Goldenberg, PhD, RPh, MS
David B. Nash, MD, MBA, describes how the “medical home” model might reduce costs associated with chronic conditions.
David B. Nash, MD, MBA
Preventing Errors with Neuromuscular Blocking Agents
In Part 1 of a two-part series, Matthew Grissinger, RPh, FASCP, reviews how mistakes in giving “high-alert” neuromuscular blocking agents can lead to serious patient harm, including paralysis.
Matthew Grissinger, RPh, FASCP
Anticompetitive Mergers, Lack of Transparency Cited
Stephen Barlas discusses ways in which Congress might target the lack of transparency and anticompetitive practices of pharmacy benefit managers (PBMs) if it passes health care reform legislation.
From Extavia to Saphris, P&T presents the latest information about FDA approvals, recalls, and industry updates.
Romiplostim (Nplate), a therapeutic option for immune (idiopathic) thrombocytopenic purpura, is reviewed.
Diana Hubulashvili, PharmD, and Nino Marzella, BS, MS, PharmD